University Procurement of 7OH in Canada: What Labs Should Know
A compound most Canadians had never heard of is suddenly in headlines on both sides of the border, and university purchasing offices are starting to get questions about it. 7-hydroxymitragynine, or 7OH, is a kratom-related alkaloid (a plant-derived chemical compound), and in July 2025 U.S. regulators moved to restrict certain 7OH products. If you run a lab, sit on a research ethics board or work in procurement, the question isn’t whether to follow the story. It’s what you have to check before a purchase order goes anywhere.
Our products are for research use only, not for human consumption. This article covers the news, the legal landscape and the paperwork questions. It isn’t legal advice.
7ohyeaSource 7OH for Laboratory Research7OH Canada provides research-grade 7OH tablets and powders, with customizable dosage options for laboratory analytical purposes.
View research materialsTL;DR
- In July 2025 the U.S. FDA recommended that the DEA schedule certain 7OH products, and the U.S. debate is still moving.
- In Canada, 7OH isn’t named in the Controlled Drugs and Substances Act as far as the primary sources we reviewed show, but that doesn’t settle your obligations. Written advice from Health Canada does.
- Universities often layer their own rules on top, including research-safety review and, where a controlled substance is involved, a federal exemption.
- Ask any supplier for batch-specific certificates of analysis, a clear research-use-only statement and Canadian origin documents before you buy.
- Procurement, research safety and the principal investigator should sign off together, not one after the other.
Table of Contents
- Quick facts
- Why is everyone suddenly talking about 7OH?
- What did the headlines get wrong?
- What does the science debate actually say?
- Is 7OH legal in Canada?
- Does a university need a federal exemption?
- What about importing it? Why does domestic sourcing come up?
- What should procurement ask before buying?
- What this means for readers
- Our perspective
- Where to find our research materials
- FAQ
- Sources
Quick facts
| Question | Short answer |
|---|---|
| What is 7OH? | A minor alkaloid in kratom leaves, also made from mitragynine in the lab and in the body |
| U.S. headline | FDA recommended scheduling certain 7OH products in July 2025 |
| Canadian status | Not named in the CDSA in the sources we checked; verify current schedules with Health Canada |
| Who to ask first | Health Canada’s Office of Controlled Substances and your institution’s research-safety office |
| Typical supplier documents | Certificate of analysis per batch, purity data, research-use-only labelling |
| Our position | Research use only, not for human consumption |
Why is everyone suddenly talking about 7OH?
Because the U.S. made it a story. In July 2025 the FDA recommended that the DEA schedule certain 7OH products as controlled substances, calling concentrated 7OH an emerging opioid threat. The same report notes that Florida issued an emergency rule that August, and that the DEA had not yet acted on the recommendation as of early September 2025.
Since then, state legislatures have kept the topic alive. A California Senate committee held an informational hearing on kratom and 7OH on 18 February 2026, and its background paper describes a regulatory gray area with enforcement gaps.
That’s the U.S. picture, and it’s worth knowing. It isn’t the Canadian one.
What did the headlines get wrong?
Three things come up again and again.
Myth: 7OH and kratom are the same thing. They’re related, not identical. The European Union Drugs Agency reports that kratom leaves contain more than 40 related alkaloids, with mitragynine the most abundant and 7OH present in very small amounts. The FDA’s scientific assessment puts natural 7OH at under 2% of total alkaloids in the leaf.
Myth: a U.S. announcement changes Canadian law. It doesn’t. A recommendation to a U.S. agency has no legal force in Canada. Canadian rules come from Canadian statutes and regulations.
Myth: if the plant is legal, the isolated alkaloid must be too. That’s an inference, not a legal finding. Health Canada’s guidance points researchers to the Act and its regulations, not to a plant’s botanical origin.
The lesson for a purchasing office is simple. Headlines are a reason to ask questions, not a source of answers.
What does the science debate actually say?
We’ll keep this to two findings, in plain language.
First, a peer-reviewed study by Kruegel and colleagues reported that the body converts mitragynine into 7OH using liver enzymes. In mice, the 7OH levels in the brain were enough to explain most of the opioid-receptor activity linked to mitragynine. Translation: researchers can’t treat mitragynine as if 7OH weren’t in the picture.
Second, a 2024 human pharmacokinetic study led by Huestis found measurable 7OH in people after they took dried kratom-leaf powder. It’s one more reason the two compounds get studied together.
The debate is real. Some scientists see 7OH as a key to understanding how kratom works. U.S. regulators see a concentrated opioid-active compound that deserves tighter control. Both views can be true at once, which is why analytical labs want well-characterised reference material in the first place.
Is 7OH legal in Canada?
Here’s what’s confirmed, and what isn’t.
The Controlled Drugs and Substances Act is the federal law that lists controlled substances in its schedules. In the Canadian primary-law sources we reviewed, 7OH doesn’t appear by name. That is not the same as a clearance. We can’t say how Health Canada would treat a given activity, and we won’t predict whether the schedules will change.
Health Canada’s controlled substances page says its framework covers legitimate scientific activities, and that research organizations may need licences and permits to carry out regulated activities. It also names the Office of Controlled Substances as the contact, and lists applications for dealer’s licences and import permits.
Health Canada has also spoken on kratom itself. Its October 2020 safety alert warned about unauthorized kratom products. That’s a consumer-product warning, and it’s a good reminder of why this category gets scrutiny.
If your institution needs certainty, get it in writing from Health Canada. Don’t rely on a supplier’s say-so, ours included.
Does a university need a federal exemption?
Sometimes, and the safest assumption is to ask early. Simon Fraser University’s research-safety office says researchers who require a controlled substance for research must obtain a subsection 56(1) exemption, and that the application process could take 6 to 8 weeks.
Two things follow for a procurement officer.
- Timelines matter. A purchase request that lands without lead time can stall a project for weeks.
- Each institution sets its own process. SFU’s page is one example, not a national rule, so check your own research-safety office.
Whether 7OH needs that route at your institution is a question for your research-safety office and Health Canada. We won’t answer it for you.
What about importing it? Why does domestic sourcing come up?
Cross-border purchasing adds a layer. The Canada Border Services Agency’s memorandum on controlled substances says that commercial importation is illegal unless authorized. It adds that controlled substances may generally be imported by licensed or registered dealers, and each shipment needs a valid import permit.
That applies if a substance is treated as controlled. It’s one reason many labs prefer a domestic supplier: no border crossing means no customs paperwork on your side. It doesn’t mean the substance is exempt from anything else.
What should procurement ask before buying?
This is where purchasing teams add the most value. A sensible checklist looks like this.
- Who has to approve it? Principal investigator, research-safety office, procurement and, where relevant, your research ethics or biosafety committees.
- Has the legal question been put to Health Canada in writing? Keep the reply on file.
- Is a federal exemption or licence needed for your project? Ask early, given the timelines above.
- Is the end use documented as analytical or laboratory only? Your purchase record should say so.
- Where does the material come from? Canadian origin means fewer customs questions and shorter lead times.
- What documents come with each batch?
On that last point, there’s no single official list, so this is our practical view as a supplier. A procurement file typically asks for:
- a certificate of analysis tied to the specific batch, ideally from a third-party laboratory;
- the stated purity of the material;
- clear research-use-only labelling;
- the supplier’s legal business name and Canadian address;
- storage and handling information for your safety office.
If a supplier can’t provide those, that’s your answer.
What this means for readers
If you’re a researcher: Start with your research-safety office, not the supplier. Ask whether your project needs an exemption, and build the 6 to 8 weeks SFU describes into your plan.
If you’re in procurement: Don’t treat U.S. headlines as Canadian rules, and don’t treat silence in a schedule as permission. Keep written Health Canada advice and a documented end use in the file.
If you’re a curious Canadian: The news is about a compound, not about something you should buy. Our materials are for research use only, not for human consumption.
Our perspective
We think the loudest part of this debate is the least useful. Headlines treat 7OH as either a scandal or a loophole. In a lab, it’s a molecule that needs to be identified, measured and documented properly.
That’s why we sell on paperwork first. We’re based in Canada, we source domestically from British Columbia, and our products are for analytical and laboratory use only. We provide batch-specific certificates of analysis, and we’d rather lose a sale than see an order placed without the right approvals behind it.
We’d also push back on a common assumption: that a clear purchase process is a hurdle. For a university, it’s protection. A clean file with a CoA, a documented end use and a written regulatory answer is what makes a purchase defensible.
If your team is reading the rules for the first time, our guides on what 7-hydroxymitragynine is and lab buying costs in Canada are good starting points.
— John
Where to find our research materials
We offer research-grade 7OH and related mitragynine alkaloid reference materials in tablet and powder form, made and sourced in Canada for laboratory use. Published pricing includes our 81% pure 7OH powder at 50 CAD and 43% pure mitragynine full-spectrum powder at 6.75 CAD. Other lines, including bulk purchasing for research teams, are listed on our research products page. All are for research use only, not for human consumption.
FAQ
Is 7OH a controlled substance in Canada?
In the primary Canadian sources we reviewed, 7OH isn’t listed by name in the Controlled Drugs and Substances Act. That doesn’t amount to legal clearance for any particular activity. Ask Health Canada’s Office of Controlled Substances for written advice and check the current schedules.
Does a university need a permit to use 7OH?
It depends on how the substance is treated and on your institution’s rules. Simon Fraser University, for example, requires a subsection 56(1) exemption for controlled substances used in research. Your research-safety office can tell you what applies to you.
Can a lab import 7OH from the U.S.?
CBSA says commercial importation of controlled substances is illegal unless authorized, and shipments need valid import permits. Whether that applies depends on the substance’s status. Buying from a Canadian supplier avoids the customs step, but not your other approvals.
What should a supplier send with the order?
At minimum, ask for a batch-specific certificate of analysis, the stated purity, research-use-only labelling and the supplier’s Canadian business details. Your safety office may want handling information too.
Are your products for human consumption?
No. Everything we sell is for research use only, not for human consumption.
Over to you: should universities set one national playbook for buying compounds like 7OH, or is the patchwork of local rules the safer bet?
Sources
- Kratom drug profile, EUDA
- 7-Hydroxymitragynin (7-OH): An Assessment of the Scientific Data, FDA
- News Brief: FDA Recommends Scheduling 7-OH Products
- Kratom and 7-Hydroxymitragynine, California Senate Committee on Health
- 7-hydroxymitragynine is an active metabolite of mitragynine
- Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics
- Controlled Drugs and Substances Act
- Controlled substances, Health Canada
- Health Canada kratom safety alert, October 2020
- Controlled substances, Simon Fraser University
- Importation and Exportation of Cannabis, Controlled Substances, CBSA
7ohyeaAsk About 7OH ProcurementEmail 7OH Canada with questions about research-grade tablets and powders, dosage options, or the company's research-use-only materials.77ohyea
Email us7ohyea@gmail.com
